CYT003, a TLR9 agonist, in persistent allergic asthma - A randomized placebo-controlled Phase 2b study

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 9, 2015, Pages 1160-1168

  Casale, T B ^a   Cole, J ^b   Beck, E ^c   Vogelmeier, C F ^d   Willers, J ^e   Lassen, C ^e   Hammann Haenni, A ^e   Trokan, L ^e   Saudan, P ^e   Wechsler, M E ^f  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b IPS Research Company   (United States)

^c Medical Department   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e CYTOS BIOTECHNOLOGY AG   (Switzerland)

^f DEPARTMENT OF MEDICINE   (United States)

Author keywords

asthma; Asthma Control Questionnaire; CpG motifs; immunotherapeutic; TLR 9 agonist

Indexed keywords

ANTIASTHMATIC AGENT; CYT 003; GLUCOCORTICOID; PLACEBO; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; CYT003-QBG10; IMMUNOLOGIC FACTOR; OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR 9;

ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE SCORE; CONTROL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE ASSESSMENT; AGONISTS; CLINICAL TRIAL; FEMALE; LUNG FUNCTION TEST; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; ASTHMA; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; RESPIRATORY FUNCTION TESTS; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME;

EID: 84940452079     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12663     Document Type: Article

References (38)

1. GINA Report. Global strategy for asthma management and prevention. Revised 2010. Available at: http://www.ginasthma.org/ReportItem.asp?l152andl252andintId594. Last accessed September 2014.
2. Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE, TENOR Study Group. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy 2007; 62: 126-133.
3. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al., Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004; 170: 836-844.
4. Bender B, Milgrom H, Rand C,. Nonadherence in asthmatic patients: is there a solution to the problem? Ann Allergy Asthma Immunol 1997; 79: 177-185.
5. Bårnes CB, Ulrik CS,. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care 2015; 60: 455-468.
6. Partridge MR,. Examining the unmet need in adults with severe asthma. Eur Respir Rev 2007; 16: 67-72.
7. Cohn L, Elias JA, Chupp GL,. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 2004; 22: 789-815.
8. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, et al., Interleukin-13: central mediator of allergic asthma. Science 1998; 282: 2258-2261.
9. Tyner JW, Kim EY, Ide K, Pelletier MR, Roswit WT, Morton JD, et al., Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. J Clin Invest 2006; 116: 309-321.
10. Grayson MH, Cheung D, Rohlfing MM, Kitchens R, Spiegel DE, Tucker J, et al., Induction of high-affinity IgE receptor on lung dendritic cells during viral infection leads to mucous cell metaplasia. J Exp Med 2007; 204: 2759-2769.
11. Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH, et al., Persistent activation of an innate immune response translates respiratory viral infection into chronic inflammatory lung disease. Nat Med 2008; 14: 633-640.
12. Bachmann MF, Jennings GT,. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010; 10: 787-796.
13. Johnson JE, Chiu W,. Structures of virus and virus-like particles. Curr Opin Struct Biol 2000; 10: 229-235.
14. Jennings GT, Bachmann MF,. The coming of age of virus-like particle vaccines. Biol Chem 2008; 389: 521-536.
15. Krieg AM,. Therapeutic potential of toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-484.
16. Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM,. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011; 10: 499-511.
17. Huber JP, Ramos HJ, Gill MA, Farrar JD,. Cutting edge: type I IFN reverses human Th2 commitment and stability by suppressing GATA3. J Immunol 2010; 185: 813-817.
18. Ito T, Yang M, Wang YH, Lande R, Gregorio J, Perng OA, et al., Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007; 204: 105-115.
19. Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Müller P, et al., Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009; 39: 562-570.
20. Klimek L, Willers J, Hammann-Haenni A, Pfaar O, Stocker H, Mueller P, et al., Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy 2011; 41: 1305-1312.
21. Beeh KM, Kanniess F, Wagner F, Schilder C, Naudts I, Hammann-Haenni A, et al., The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol 2013; 131: 866-874.
22. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al., Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
23. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC,. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for steel and coal. official statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 5-40.
24. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al., An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184: 602-615.
25. Juniper EF, Bousquet J, Abetz L, Bateman ED, GOAL Committee. Identifying «well-controlled» and «not well-controlled» asthma using the Asthma Control Questionnaire. Respir Med 2006; 100: 616-621.
26. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al., Lebrikizumab treatment in adults with asthma. New Engl J Med 2011; 365: 1088-1098.
27. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, et al., A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181: 788-796.
28. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al., A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013; 41: 330-338.
29. Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al., A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176: 1062-1071.
30. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, et al., Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003; 167: 1655-1659.
31. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al., Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011; 154: 573-582.
32. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al., Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993.
33. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al., Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.
34. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al., Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184: 1125-1132.
35. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H,. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125: 1378-1386.
36. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al., Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455-2466.
37. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al., Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198-1207.
38. Kanniess F, Richter K, Janicki S, Schleiss MB, Jörres RA, Magnussen H,. Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma. Eur Respir J 2002; 20: 1080-1087.